Design and development of novel inhibitors of aldo-ketoreductase 1C1 as potential lead molecules in treatment of breast cancer
- 26 March 2021
- journal article
- research article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 476 (8) , 2975-2987
Abstract
Aldo–keto reductase 1C1 (AKR1C1) is a hydroxysteroid dehydrogenase, known to inactivate the biologically active progesterone into its corresponding 20 α-hydroxyprogesterone. Increased expression of the AKR1C1 gene in oncogenesis is linked with resistance to various anticancer agents and hence it is considered as an emerging drug target for the design and developing the novel anticancer drugs. We have performed QSAR pharmacophore modeling for AKR1C1 inhibitors followed by a virtual screening of ~ 59,000 compounds present at the Maybridge database. The screened compounds were refined using drug-like filters of Lipinski rule, ADMET plot, molecular docking and scoring and subsequently top 20 hits were selected. Selected compounds were subjected to the in vitro for AKR1C1 inhibition assay and best seven compounds bearing excellent binding affinity to the AKR1C1 were finally selected. The identified compounds may be exploited in hit-to-lead development and may also prove as an interventional strategy in preventing a pre-term birth due to declining levels of progesterone.Keywords
Funding Information
- Department of Health Research (No: V.25011/450-HRD/2016-HR)
This publication has 49 references indexed in Scilit:
- Progesterone Receptor-A and -B Have Opposite Effects on Proinflammatory Gene Expression in Human Myometrial Cells: Implications for Progesterone Actions in Human Pregnancy and ParturitionThe Journal of Clinical Endocrinology & Metabolism, 2012
- Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancerBioorganic & Medicinal Chemistry Letters, 2012
- Development of Potent and Selective Inhibitors of Aldo–Keto Reductase 1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase) Based onN-Phenyl-Aminobenzoates and Their Structure–Activity RelationshipsJournal of Medicinal Chemistry, 2012
- Cervical cancer in India and HPV vaccinationIndian Journal of Medical and Paediatric Oncology, 2012
- FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell CarcinomaThe Oncologist, 2010
- Minireview: Fetal-Maternal Hormonal Signaling in Pregnancy and LaborMolecular Endocrinology, 2009
- Selectivity Determinants of Inhibitor Binding to Human 20α-Hydroxysteroid Dehydrogenase: Crystal Structure of the Enzyme in Ternary Complex with Coenzyme and the Potent Inhibitor 3,5-Dichlorosalicylic AcidJournal of Medicinal Chemistry, 2008
- AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancerMolecular and Cellular Endocrinology, 2006
- Selective and potent inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesteroneChemico-Biological Interactions, 2003
- Pharmacophore Perception, Development and Use in Drug Design. Edited by Osman F. GünerMolecules, 2000